KaydedilenlerDerginizi ekleyin

Dergiler / Etlik Veteriner Mikrobiyoloji Dergisi / 2019 / Cilt: 30 - Sayı: 1

Antiviral İlaçlar

Antiviral Drug

Ali KÜÇÜK
Yakup YILDIRIM
Sayfa
100–108
Yayın Tarihi
2019-06-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim
📊
Temel Bulgular & Veri:Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim
💡
Sonuç & Katkı:Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Antiviral ilaç · virüs · Antiviral drug

Özet

Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim

Abstract

Throughout history, viral diseases have always threatened lives of all humans and living beings in contact with them causing epidemics and pandemics. These epidemics that caused death or destruction of millions of living beings also brought about the need for protection and treatment. Technological and health opportunities that started to develop at the beginning of the 20st century made it possible to convey studies and research on treatment of viral diseases. In this composition, information has been provided about antiviral agents developed to be used in treatment of viral infections threatening human and animal health.

🔖

Bu Makaleye Atıf Yap

KÜÇÜK, A., YILDIRIM, Y. (2019). Antiviral İlaçlar. Etlik Veteriner Mikrobiyoloji Dergisi, Cilt: 30 - Sayı: 1, 100–108. https://ajindex.com/articles/118592

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Adalsteinsson JA, Pan M, Kaushik S, Ungar J, (2018). Foscarnet-induced genital lesions: An overview with a case report. Dermatol Reports.10, 12-13.
  2. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD, (2010). Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents. Ann Pharmacother. 44, 157–165.
  3. Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA, (2018). Proteases and protease inhibitors in infectious dis- eases. Med Res Rev. 38, 1295-1331. Air GM, (2012), İnfluenza neuraminidase. İnfluenza Other Respir Virus. 6,245-256.
  4. Al-Badr AA, Ajarim TDS, (2018). Ganciclovir. Brittin HG. Eds. Profiles of Drug Substances, Excipients and Related Methodology vol 43. Academic Press Inc, USA, 1-208.
  5. Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini J, Snoeck R, (2005). Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidinenucleosides, Antimicrob Agents Chemother. 49, 1081–1086.
  6. Angus P, Vaughan R, Xıong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S, (2003). Resistance to Adefovir Dipivoxil Therapy Associated With the Selection of a Novel Mutation in the HBV Polymerase. Gastroenterology. 125, 292-297.
  7. Arslan U, Ural O, Fındık D, (2008). Lamivudin tedavisi alan kronik hepatit B olgularında inno-lipa HBV DR yöntemi ile saptanan YMDD motif değişiklikleri, Mikrobiyol Bul. 42, 445-450.
  8. Berkhout B, Eggink D, Sanders RW, (2012). Is there a future for antiviral fusion inhibitors. Białek-Pietras M, Olejniczak AB, Paradowska E, Studzinska M, Jabłonska A, Lesnikowski ZJ, (2018). Synthesis, suscep- tibility to enzymatic phosphorylation, cytotoxicity and in vitro antiviral activity of lipophilic pyrimidine nucleoside/ carborane conjugates. J Organomet Chem. 865, 166-172.
  9. Chang T, Gish R, De Man R, (2006). A comparison of ente- cavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010. 12. Charpentier C, Camacho R, Ruelle J, Eberle J, Gurtler L, Pironti A, Sturmer M, Brun-Vezinet F, Kaiser R, Descamps D, Obermeier M, (2015). HIV-2EU-supporting standard- ized HIV-2 drug-resistance interpretation in Europe: an update. Clin Infect Dis. 61, 1346-1347.
  10. Chou TY, Hong BY, (2014). Ganciclovir ophthalmic gel %0.15 for the treatment of acute herpetic keratitis: back- ground, effectiveness, tolerability, safety, and future appli- cations. Ther Clin Risk Manag. 10, 665–681. Cih